Ironing out a therapy for Friedreich ataxia

Blood

Volumn 110, Issue 1, 2007, Pages 1-2

  Isaya, Grazia ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; FRATAXIN; IRON CHELATING AGENT; MITOCHONDRIAL PROTEIN;

CEREBELLUM; DENTATE NUCLEUS; FRDA GENE; FRIEDREICH ATAXIA; GENE; HUMAN; INTRON; IRON CHELATION; IRON DEPLETION; IRON METABOLISM; IRON OVERLOAD; MEMBRANE PERMEABILITY; MITOCHONDRIAL RESPIRATION; NEUROLOGIC DISEASE; NOTE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY;

EID: 34347390211     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-04-084509     Document Type: Note

References (4)

1. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423-1427.
2. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet. 1999;354:477-479.
3. Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR. Newborn screening: toward a uniform screening panel and system. Genet Med. 2006;8:1S-11S.
4. Green NS, Pass KA. Neonatal screening by DNA microarray: spots and chips. Nat Rev Genet. 2005;6:147-151.